USA flag logo/image

An Official Website of the United States Government

Recombinant ISA Virus Vaccine

Award Information

Agency:
Department of Agriculture
Branch:
N/A
Award ID:
62049
Program Year/Program:
2003 / SBIR
Agency Tracking Number:
2003-00478
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Maine BioTek, Inc.
259 MAIN STREET Suite 208 WINTERPORT, ME 04496 0408
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2003
Title: Recombinant ISA Virus Vaccine
Agency: USDA
Contract: 2003-33610-13059
Award Amount: $75,000.00
 

Abstract:

NON-TECHNICAL SUMMARY: ISA virus, an unclassified Orthomyxoviridae is an emerging pathogen associated with disease in farmed Atlantic salmon. Losses incurred in Maine due to ISA alone in 2002 are estimated to be over $12 million (US). In response to the threat, salmon producers have stated that an ISAV vaccine is needed. The ultimate success of the project will be the construction of a safe, efficacious, recombinant ISA virus vaccine. Evaluation of vaccine efficacy will involve assessing the humoral immune response post-vaccination and post-challenge, measuring virus clearance post-challenge and determining the relative percent survival in vaccinated fish post-challenge. An efficacious ISAV vaccine would provide a disease management tool that in combination with good fish health practices would ensure the sustainability of the salmon aquaculture industry in North America. The vaccine could also form an integral component of adaptive management strategies for the protection and recovery of endangered Atlantic salmon in Maine.

Principal Investigator:

Sharon Clouthier
2072234662
sclouthier@hotmail.com

Business Contact:

Sharon Clouthier
President
2072234662
sclouthier@hotmail.com
Small Business Information at Submission:

Maine BioTek, Inc.
P.O. Box 408, 259 Main Street Winterport, ME 04496

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No